Martin Huber
2022 - Xilio Therapeutics
In 2022, Martin Huber earned a total compensation of $1.3M as President and Head of R&D at Xilio Therapeutics, a 61% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $242,500 |
|---|---|
| Option Awards | $607,499 |
| Salary | $488,638 |
| Other | $8,872 |
| Total | $1,347,509 |
Huber received $607.5K in option awards, accounting for 45% of the total pay in 2022.
Huber also received $242.5K in non-equity incentive plan, $488.6K in salary and $8.9K in other compensation.
Rankings
In 2022, Martin Huber's compensation ranked 2,449th out of 5,717 executives tracked by ExecPay. In other words, Huber earned more than 57.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,449 out of 5,717 | 57th |
Division Manufacturing | 1,342 out of 3,111 | 57th |
Major group Chemicals And Allied Products | 603 out of 1,410 | 57th |
Industry group Drugs | 557 out of 1,311 | 58th |
Industry Pharmaceutical Preparations | 399 out of 957 | 58th |
Source: SEC filing on April 25, 2023.
Huber's colleagues
We found two more compensation records of executives who worked with Martin Huber at Xilio Therapeutics in 2022.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022